Manufacturers make rolling new drug submission to FDA for pacritinib in myelofibrosis patients with severe thrombocytopenia

Data for the FDA review of this oral kinase inhibitor (with specificity for JAK2, IRAK1, and CSF1R) will come from the phase III PERSIST-1 and PERSIST-2, and the phase II PAC203 trials

Source:

Biospace Inc.